Patents by Inventor Kumaravel Selvakumar

Kumaravel Selvakumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-substituted propionic acids as ?V integrin inhibitors
    Patent number: 11884661
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?V-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: January 30, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guohua Zhao, Pratik Devasthale, Xiang-Yang Ye, Kumaravel Selvakumar, Suresh Dhanusu, Palanikumar Balasubramanian, Leatte R. Guernon, Rita Civiello, Xiaojun Han, Michael Frederick Parker, Swanee E. Jacutin-Porte
  • CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS
    Publication number: 20230390249
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: August 22, 2023
    Publication date: December 7, 2023
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • HETEROCYCLIC PAD4 INHIBITORS
    Publication number: 20230167131
    Abstract: The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 1, 2023
    Inventors: Kumaravel Selvakumar, Venkatram Paidi, Srinivasan Thangathirupathy, Vijaya Kumar Cm, Tirupathi Rao Alajangi, Mallikarjun Reddy Sura, Krishna Mahadevu, Ramesh Kumar Sistla, Piyush Agarwal, Arul Mozhi Subbiah Karuppiah, Jalathi S. Nair, Ooha Morampudi, Manoranjan Panda, Joseph A. Tino, Robert J. Cherney, John V. Duncia, Daniel S. Gardner, T. G. Murali Dhar, Audrey Graham Ross, Paul E. Gormisky, Xiao Zhu, Boris M. Seletsky, Alyssa H. Antropow, Deqiang Niu, Zhengdong Zhu, Guobin Miao, Julio Herman Cuervo
  • Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as ?V integrin inhibitors
    Patent number: 11639353
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 2, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pratik Devasthale, Fang Moore, Guohua Zhao, Susan Nicole Pieniazek, Kumaravel Selvakumar, Suresh Dhanusu, Manoranjan Panda, Lawrence R. Marcin
  • CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS
    Publication number: 20220249443
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: April 12, 2022
    Publication date: August 11, 2022
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Benzofuran derivatives for the treatment of hepatitis C
    Patent number: 11161837
    Abstract: The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: November 2, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Kap-Sun Yeung, John F. Kadow, Rajesh Onkardas Bora, Prakash Anjanappa, Kumaravel Selvakumar, Samayamunthula Venkata Satya Arun Kumar Gupta
  • CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS
    Publication number: 20210246136
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: March 25, 2021
    Publication date: August 12, 2021
    Inventors: Pratik Devasthale, Fang Moore, Guohua Zhao, Susan Nicole Pieniazek, Kumaravel Selvakumar, Suresh Dhanusu, Manoranjan Panda, Lawrence R. Marcin
  • CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS
    Publication number: 20210244711
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: April 5, 2021
    Publication date: August 12, 2021
    Inventors: PETER TAI WAH CHENG, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS
    Publication number: 20210188847
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?V-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: February 24, 2021
    Publication date: June 24, 2021
    Inventors: Guohua Zhao, Pratik Devasthale, Xiang-Yang Ye, Kumaravel Selvakumar, Suresh Dhanusu, Palanikumar Balasubramanian, Leatte R. Guernon, Rita Civiello, Xiaojun Han, Michael Frederick Parker, Swanee E. Jacutin-Porte
  • Cyclobutane- and azetidine-containing mono and spirocyclic compounds as ?V integrin inhibitors
    Patent number: 11014922
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: May 25, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pratik Devasthale, Fang Moore, Guohua Zhao, Susan Nicole Pieniazek, Kumaravel Selvakumar, Suresh Dhanusu, Manoranjan Panda, Lawrence R. Marcin
  • Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
    Patent number: 11007180
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • 3-substituted propionic acids as ?V integrin inhibitors
    Patent number: 10968219
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: April 6, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guohua Zhao, Pratik Devasthale, Xiang-Yang Ye, Kumaravel Selvakumar, Suresh Dhanusu, Palanikumar Balasubramanian, Leatte R. Guernon, Rita Civiello, Xiaojun Han, Michael Frederick Parker, Swanee E. Jacutin-Porte
  • BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20200291002
    Abstract: The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: March 17, 2017
    Publication date: September 17, 2020
    Inventors: Kap-Sun Yeung, John F. Kadow, Rajesh Onkardas Bora, Prakash Anjanappa, Kumaravel Selvakumar, Samayamunthula Venkata Satya Arun Gupta
  • CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS
    Publication number: 20200138789
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: January 2, 2020
    Publication date: May 7, 2020
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
    Patent number: 10576062
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: March 3, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS
    Publication number: 20190270741
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: November 7, 2017
    Publication date: September 5, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Pratik DEVASTHALE, Fang MOORE, Guohua ZHAO, Susan Nicole PIENIAZEK, Kumaravel SELVAKUMAR, Suresh DHANUSU, Manoranjan PANDA, Lawrence R. MARCIN
  • 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS
    Publication number: 20190263808
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: November 7, 2017
    Publication date: August 29, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Guohua ZHAO, Pratik DEVASTHALE, Xiang-Yang YE, Kumaravel SELVAKUMAR, Suresh DHANUSU, Palanikumar BALASUBRAMANIAN, Leatte R. GUERNON, Rita CIVIELLO, Xiaojun HAN, Michael Frederick PARKER, Swanee E. JACUTIN-PORTE
  • CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS
    Publication number: 20180333395
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: July 18, 2018
    Publication date: November 22, 2018
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
    Patent number: 10071078
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: September 11, 2018
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
    Patent number: RE49352
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: January 3, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Badu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf